What Fueled Antibody Drug Conjugates Market?
The antibody drug conjugates market has seen considerable growth due to a variety of factors.
• The dimension of the antibody drug conjugates market has magnified tremendously in the past few years. The market's growth is projected to increase from $13.57 billion in 2024 to $16.66 billion in 2025, with a compound annual growth rate (CAGR) of 22.7%.
The remarkable growth during the historic stretch can be ascribed to the mounting prevalence of cancer, triumphant clinical outcomes and approvals, carefully planned collaborations, amplified investment in research and development, and tactics for market expansion.
What is the Market Size Forecast for the Antibody Drug Conjugates Market?
The antibody drug conjugates market is expected to maintain its strong growth trajectory in upcoming years.
• The size of the market for antibody drug conjugates is anticipated to witness a significant surge in the coming years, reaching $38.39 billion in 2029 with a compound annual growth rate (CAGR) of 23.2%.
The expansion during the prediction period might be due to the emergence of next-generation ADCS, burgeoning indications, a heightened emphasis on personalized treatment, increased investment in precision medicine, and a boost in health awareness. Key tendencies during this period will be advancements in conjugation technologies, enhanced comprehension of tumor biology, technological breakthroughs, broadening therapeutic application, and advanced conjugation technologies.
What Are the Critical Driver Fuelling the Antibody Drug Conjugates Market's Growth?
Globally, the major factors propelling the antibody-drug conjugates market include escalating cases of cancer. Some of the prominent causes of various types of cancer are obesity, smoking, alcohol consumption, and unhealthy dietary practices. Cancer Research UK forecasts that the annual new cancer cases will reach 27.5 million by the year 2040. As a result, the continuous increase in cancer cases is anticipated to elevate the demand for antibody-drug conjugates, thus, bolstering the growth of the market.
What Are The Major Segments Within The Antibody Drug Conjugates Market?
The antibody drug conjugates market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types
2) By Product: Adcertis, Kadcyla, Other Products
3) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology
4) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications
5) By End User: Hospital, Clinics, Other End Users
Subsegments:
1) By Monoclonal Antibodies: IgG-based Monoclonal Antibodies, IgM-based Monoclonal Antibodies, Bispecific Antibodies
2) By Linker: Cleavable Linkers, Non-cleavable Linkers, Stable Linkers
3) By Drug/Toxin: Cytotoxic Drugs, Chemotherapeutic Agents, Radioisotopes
4) By Other Types: Enzyme-Targeted ADCs, Antibody-Drug Conjugates with Immune Modulators
Pre-Book The Antibody Drug Conjugates Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Antibody Drug Conjugates Market?
The production of antibody-drug conjugates is overseen by multiple regulatory entities, like the Food and Drug Administration in America. There lacks specific guidance for ADC development within the USA, with the FDA relying on pre-existing regulations for smaller drugs and monoclonal antibodies for managing ADC. Groups within the FDA, such as the Office of Biotechnology Products (OBP) and Office of Pharmaceutical Quality, center their attention primarily on the ADC’s antibody component manufacture and control strategy for the antibody intermediate, as well as for the drug substance (DS) and drug product (DP). The payload and linker's adequacy, the conjugation reactions, and control strategy elements are primarily reviewed by small molecule review groups within the Office of Pharmaceutical Quality.
Who Are the Key Players in the Antibody Drug Conjugates Market?
Major companies operating in the antibody drug conjugates market include:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Millennium Pharmaceuticals Inc.
• Gilead Sciences Inc.
• Daiichi Sankyo Company Limited
• Sorrento Therapeutics Inc.
• Astellas Pharma Inc.
• Zydus Lifesciences Limited
• Seagen Inc.
• Seagen Inc.
• Synthon BV
• Genentech Inc.
• ImmunoGen Inc.
• Nordic Nanovector ASA
• ADC Therapeutics SA
• Immunomedics Inc.
• Mersana Therapeutics Inc.
• Heidelberg Pharma AG
• Celldex Therapeutics Inc.
• Oxford BioTherapeutics
• Concortis Biotherapeutics Corp.
• Antikor BioPharma Ltd.
• Eisai Co. Ltd.
• Merck KGaA
What Is The Most Dominant Region In The Antibody Drug Conjugates Market?
North America was the largest region in the antibody-drug conjugates (ADCs) market in 2024. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
